Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 7, 2020; 26(41): 6346-6360
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6346
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6346
Control | CCl4 | Vehicle | DHM | |
TC (mmol/L) | 1.77 ± 0.12 | 2.22 ± 0.17a | 2.21 ± 0.16a | 1.87 ± 0.19c |
TG (mmol/L) | 0.80 ± 0.13 | 0.82 ± 0.11 | 0.72 ± 0.20 | 0.75 ± 0.20 |
LDL (mmol/L) | 0.12 ± 0.03 | 0.30 ± 0.04a | 0.34 ± 0.11a | 0.23 ± 0.01b |
HDL (mmol/L) | 1.51 ± 0.09 | 1.44 ± 0.07 | 1.25 ± 0.28 | 1.31 ± 0.29 |
ALT (U/L) | 119.87 ± 22.26 | 367.40 ± 21.15a | 415.42 ± 45.03a | 213.52 ± 31.82c |
AST (U/L) | 126.05 ± 25.60 | 1790.30 ± 376.01a | 1995.52 ± 273.80a | 615.65 ± 170.62c |
- Citation: Cheng QC, Fan J, Deng XW, Liu HC, Ding HR, Fang X, Wang JW, Chen CH, Zhang WG. Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis. World J Gastroenterol 2020; 26(41): 6346-6360
- URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6346.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6346